LLY — Eli Lilly and Company $1,199.43

Generated 2026-06-30 21:49
USAIND

Quality Scorecard Growth

A96/100
✅ Pricing power (gross margin) 83% Gross margin 83% — wide margins, likely pricing power
✅ Return on equity 107% ROE 107% — high returns on capital
✅ Leverage (net debt / EBITDA) 1.1x Net debt / EBITDA 1.1x — low leverage
✅ Interest coverage 38x EBIT covers interest 38x — comfortably covered
✅ Earnings consistency (revenue) 0/3 down 0 revenue-down year(s) in 3 — no down years
✅ Earnings growth (net income YoY) +95% Net income +95% YoY — earnings growing
🟡 Cash conversion (CFO/NI) 81% Operating cash ÷ net income 81% — moderate conversion
✅ Operating margin trend improving Operating margin improving
✅ Revenue growth 56% Revenue +56% — strong demand growth
✅ Growth trajectory accelerating YoY +45% vs +26% prior 2-yr avg — accelerating
✅ Dilution control -0.8%/yr Shares -0.8% YoY — dilution controlled
✅ Rule of 40 65 growth 56% + FCF margin 9% = 65 — healthy growth + profitability

Growth-stage checklist (proxy metrics from yfinance). 12 of 12 criteria scored. Not financial advice.

Buy-Now Score

80/100
Quality ×40%96
Trajectory ×30%100
Valuation ×30%37

Comparative rank: 40% Quality + 30% Trajectory + 30% Valuation — higher = better buy now. Not financial advice.

Valuation

$304.77$1,344.88
Price $1,199.43DCF $338.63 (-72%)Analyst $1,222.62 (+2%)MarketGist fair $1,045.82 (-13%)

DCF: 38% start growth → 2.5%, 7.1% discount (band $249.31–$428.07). Analyst: 29 analysts. MarketGist fair = 80% analyst + 20% DCF. Not financial advice.

Key Trends (6-yr)

GAAP EPS
▲ +96.0% YoY
Sales
▲ +44.7% YoY
Shares Outstanding
▼ -0.5% YoY

Company Overview

Basic Information

Company Name: Eli Lilly and Company
Symbol: LLY
Exchange: NYQ
Sector: Healthcare
Industry: Drug Manufacturers - General

Company Details

Country: United States
City: Indianapolis
Employees: 50,000
Market Cap: $1.07T
Website: https://www.lilly.com

Business Description

Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, such as Cyramza for the second-line treatment of gastric cancer or gastro-esophageal junction adenocarcinoma; Erbitux for colorectal cancers and head and neck cancers; Inluriyo for breast cancer; Jaypirca for chronic lymphocytic leukemia or small lymphocytic lymphoma; Retevmo for the treatment of metastatic NSCLC; TYVYT for classic hodgkin's lymphoma; and Verzenio for breast cancer. In addition, the company offers immunology products, which include Ebglyss for severe atopic dermatitis; Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Omvoh for ulcerative colitis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. Further, it provides Emgality for migraine prevention and episodic cluster headache, as well as Kisubla for symptomatic Alzheimer's disease. The company has collaborations with Boehringer Ingelheim Pharmaceuticals, Inc. for the Jardiance product family; and F. Hoffmann-La Roche Ltd and Genentech, Inc. for lebrikizumab, as well as license agreements with Almirall, S.A. for Ebglyss; and Chugai Pharmaceutical Co., Ltd for orforglipron; strategic collaboration with Ascidian Therapeutics for development of therapies for undisclosed monogenic kidney diseases; and BioArctic AB (publ) for new treatment. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.

Key Metrics

Price & Valuation

Current Price
$1.20K
Market Cap
$1.07T
P/E Ratio
42.58
Forward P/E
26.97
PEG Ratio
1.56
Price to Book
34.35

Profitability

Profit Margin: 34.99%
Operating Margin: 49.39%
Gross Margin: 82.83%
Return on Equity (ROE): 107.46%
Return on Assets (ROA): 20.74%
Revenue Growth: 55.50%

Financial Health

Current Ratio: 1.50
Quick Ratio: 0.72
Debt to Equity: 139.01
Total Debt: $43.37B
Total Cash: $5.28B
Beta: 0.52

Trading & Analyst Info

52-Week Range

52-Week High: $1.24K
52-Week Low: $623.78
50-Day Average: $1.04K
200-Day Average: $978.29

Analyst Recommendations

Recommendation: BUY
Target Mean Price: $1.22K
Target High: $1.50K
Target Low: $850.00

Price graph

Price vs Rates, Inflation & Volume (long-term)

Dotted = market-implied expectation (next ~12 mo), not a prediction.

Quarterly Verdict

🟢 100/100

Worth buying

Quality grade A; 5 improving / 1 weakening metrics YoY.

➕ Pricing power (gross margin): Gross margin 83% — wide margins, likely pricing power
➕ Return on equity: ROE 107% — high returns on capital
➕ Leverage (net debt / EBITDA): Net debt / EBITDA 1.1x — low leverage
➕ Interest coverage: EBIT covers interest 38x — comfortably covered
➕ Earnings consistency (revenue): 0 revenue-down year(s) in 3 — no down years
➕ Earnings growth (net income YoY): Net income +95% YoY — earnings growing
➕ Operating margin trend: Operating margin improving
➕ Revenue growth: Revenue +56% — strong demand growth
➕ Growth trajectory: YoY +45% vs +26% prior 2-yr avg — accelerating
➕ Dilution control: Shares -0.8% YoY — dilution controlled
➕ Rule of 40: growth 56% + FCF margin 9% = 65 — healthy growth + profitability
➕ Revenue +55.5% YoY
➕ Net income +168.1% YoY
➕ Operating margin +7.7 pts YoY
➕ Free cash flow +275.1% YoY
➕ Cash +70.8% YoY
➖ Debt +12.6% YoY

Heuristic from the Quality Scorecard + quarter-over-quarter trends. Not financial advice.

Financial Statements

Income Statement (Annual)

Item2025-12-312024-12-312023-12-312022-12-312021-12-31
Tax Effect Of Unusual Items$-671.52M$-682.55M$-777.47M$-129.80MN/A
Tax Rate For Calcs$0.20$0.16$0.20$0.08N/A
Normalized EBITDA$35.09B$22.95B$15.72B$10.22BN/A
Total Unusual Items$-3.39B$-4.14B$-3.87B$-1.56BN/A
Total Unusual Items Excluding Goodwill$-3.39B$-4.14B$-3.87B$-1.56BN/A
Net Income From Continuing Operation Net Minority Interest$20.64B$10.59B$5.24B$6.24BN/A
Reconciled Depreciation$2.00B$1.77B$1.53B$1.52BN/A
Reconciled Cost Of Revenue$11.05B$8.42B$7.08B$6.63BN/A
EBITDA$31.69B$18.81B$11.85B$8.66BN/A
EBIT$29.70B$17.04B$10.32B$7.14BN/A
Net Interest IncomeN/A$-605.40M$-312.30M$-268.80M$-314.40M
Interest ExpenseN/A$780.60M$485.90M$331.60M$339.80M
Interest IncomeN/A$175.20M$173.60M$62.80M$25.40M
Normalized Income$23.36B$14.05B$8.33B$7.68BN/A
Net Income From Continuing And Discontinued Operation$20.64B$10.59B$5.24B$6.24BN/A

Showing 15 of 51 rows

Balance Sheet (Annual)

Item2025-12-312024-12-312023-12-312022-12-312021-12-31
Treasury Shares Number$50.00M$50.37M$50.40M$450.00KN/A
Ordinary Shares Number$894.80M$897.54M$899.38M$950.18MN/A
Share Issued$944.80M$947.90M$949.78M$950.63MN/A
Net Debt$35.23B$30.38B$22.41B$14.17BN/A
Total Debt$42.50B$33.64B$25.23B$16.24BN/A
Tangible Book Value$14.12B$2.34B$-1.07B$-629.80MN/A
Invested Capital$69.04B$47.92B$36.00B$26.89BN/A
Working Capital$20.40B$4.36B$-1.57B$896.30MN/A
Net Tangible Assets$14.12B$2.34B$-1.07B$-629.80MN/A
Common Stock Equity$26.54B$14.27B$10.77B$10.65BN/A
Total Capitalization$67.40B$42.80B$29.09B$25.39BN/A
Total Equity Gross Minority Interest$26.54B$14.27B$10.86B$10.78BN/A
Minority InterestN/A$79.50M$91.80M$125.60M$175.60M
Stockholders Equity$26.54B$14.27B$10.77B$10.65BN/A
Other Equity Interest$-2.99B$-2.98B$-3.01B$-3.01BN/A

Showing 15 of 84 rows

Cash Flow Statement (Annual)

Item2025-12-312024-12-312023-12-312022-12-312021-12-31
Free Cash Flow$5.96B$414.00M$-3.15B$4.60BN/A
Repurchase Of Capital Stock$-4.11B$-2.50B$-750.00M$-1.50BN/A
Repayment Of Debt$-778.00M$-664.00M$0.00$-1.56BN/A
Issuance Of Debt$13.17B$11.42B$3.96B$0.00N/A
Capital Expenditure$-10.85B$-8.40B$-7.39B$-2.99BN/A
End Cash Position$7.27B$3.27B$2.82B$2.07BN/A
Beginning Cash Position$3.27B$2.82B$2.07B$3.82BN/A
Effect Of Exchange Rate Changes$372.00M$-297.00M$169.00M$-167.60MN/A
Changes In Cash$3.63B$746.00M$583.00M$-1.58BN/A
Financing Cash Flow$-2.21B$1.23B$3.50B$-5.41BN/A
Cash Flow From Continuing Financing Activities$-2.21B$1.23B$3.50B$-5.41BN/A
Net Other Financing Charges$-772.00M$-491.00M$-335.00M$-308.90MN/A
Cash Dividends Paid$-5.38B$-4.68B$-4.07B$-3.54BN/A
Common Stock Dividend Paid$-5.38B$-4.68B$-4.07B$-3.54BN/A
Net Common Stock Issuance$-4.11B$-2.50B$-750.00M$-1.50BN/A

Showing 15 of 57 rows

Data via yfinance. Prices may be delayed. · Privacy

Disclaimer: MarketGist is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice, nor a recommendation, offer, or solicitation to buy or sell any security. Data is sourced automatically (e.g. via yfinance and other third parties) and may be delayed, inaccurate, or incomplete. Investing involves risk, including the possible loss of principal; past performance does not guarantee future results. MarketGist is not a registered investment adviser or broker-dealer. Always do your own research and consult a licensed financial professional before making any investment decision. By using this site you agree that MarketGist and its authors accept no liability for any loss or damage arising from reliance on its content.